🗓️ Crescent is heading to London later this month to give a presentation at the Jefferies London Healthcare Conference, held November 19-24. Management will present on Tuesday, November 19, 2024, at 12:30 pm GMT/7:30 am EDT. A live webcast will be available here: https://lnkd.in/eqKMcEZM, and made available for 90 days. Read the release: https://lnkd.in/eHJpPVAM We hope to see you there. #JefferiesHealthcare #JefferiesHealthcareConference #Investors #Biotech
Crescent Biopharma
Biotechnology Research
Illuminating a brighter future for treating solid tumors with potentially best-in-class therapies.
About us
- Website
-
www.crescentbiopharma.com
External link for Crescent Biopharma
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Crescent Biopharma
Updates
-
The Crescent Board is growing! Former Chief Medical Officer of RayzeBio Susan Moran, M.D., MSCE, and CFO of Nuvalent Alex Balcom, MBA, CPA, have been named as Board Directors. They will serve alongside Crescent Interim CEO Jonathan Violin, PhD, and Fairmount’s Peter Harwin. The Board composition reflects our commitment to rapidly advancing clinical operations in order to deliver next-generation cancer treatments. Read the full release here: https://lnkd.in/eajAyRMy Welcome aboard! #CancerTreatments #Team #BoardAppointments #Biotech
-
-
📢 NEWS: GlycoMimetics has announced an agreement to acquire Crescent Biopharma and advance Crescent’s portfolio of novel biologics precision engineered to improve outcomes for patients with solid tumors — delivering superior efficacy to the current gold standard. Upon completion of the merger, the unified company will operate as Crescent, progressing lead assets CR-001, a cooperative PD-1 x VEGF bispecific antibody and CR-002, an antibody-drug conjugate for an undisclosed target with a topoisomerase inhibitor payload that may offer best-in-class efficacy. With a concurrent private financing of approximately $200 million led by Fairmount Funds Management LLC, Venrock, BVF PARTNERS, L.P, and a large investment management firm, Crescent expects to fund operations through 2027. Read the release here: https://lnkd.in/eHRSNgjp Learn more at www.crescentbiopharma.com. #SolidTumors #Oncology #CancerCare #Merger #Biotech
-